Research progress on traditional Chinese medicine intervention in acute myocardial infarction based on syndrome differentiation and treatment

Background Acute myocardial infarction (AMI) corresponds to chest impediment and true heart pain in traditional Chinese medicine (TCM), a critical cardiovascular emergency with the core pathogenesis of deficiency in origin and excess in manifestation and six major clinical syndrome patterns. Guideline-directed medical therapy including reperfusion and pharmacotherapy serve as the primary emergency strategy for rescuing ischemic myocardium; nevertheless, drug-related adverse reactions and persistent post-infarction symptomatic complaints remain prevalent. TCM formulae exert multimodal myocardial-protective bioactivities supported mainly by preclinical evidence and can relieve residual discomforts when used as add-on complementary intervention. This highlights the clinical value of pattern identification-based therapeutic management-guided integrated Chinese-Western intervention for AMI. Stand-alone herbal-based TCM intervention cannot replace urgent guideline-directed reperfusion and pharmacological interventions. Aim of the review This narrative review aims to narratively synthesize existing evidence for guideline-directed western-only therapy, TCM adjuvant intervention, and integrated Chinese-Western medicine for AMI, elaborate potential cardioprotective mechanisms of representative TCM prescriptions derived from preclinical experimental observations, analyze superimposed safety risks caused by herbal-western drug concomitant use, and identify prominent evidence gaps, so as to provide theoretical references for standardized integrated Chinese-Western clinical management of AMI. Materials and methods Literature was narratively collected from CNKI and PubMed from database inception up to June 30, 2026. Studies covering preclinical and clinical evidence of guideline-directed western medicine, stand-alone herbal-based TCM intervention, and combined Chinese-Western interventions for AMI were included. Literature screening, data extraction, and narrative synthesis were performed for therapeutic efficacy, cardioprotective mechanisms, and herb-drug interaction risks; major limitations of current research were further summarized. This is not a systematic review. Results preclinical experimental observations suggest multi-target cardioprotective properties of TCM herbs and compound formulae and cannot be directly extrapolated to human clinical outcomes. Available clinical evidence indicates that syndrome-differentiation-guided TCM as an add-on to standard guideline-directed western therapy can alleviate residual discomforts during AMI convalescence, whereas stand-alone herbal-based TCM intervention cannot replace urgent western reperfusion and pharmacological interventions. The high-quality CTS-AMI trial supports adjuvant benefits for Tongxinluo only and cannot be generalized to all TCM herbal preparations. Current research drawbacks include non-unified syndrome-differentiation criteria, insufficient large-sample long-term cohorts focusing on robust clinical outcome metrics, inadequate safety data concerning herbal-western drug concomitant use, publication bias, and heterogeneity across preclinical and clinical studies. Conclusion This review compares the merits and limitations of three interventional modalities for AMI, interprets the theoretical basis and practical value of pattern identification-based therapeutic management-based TCM adjuvant treatment, and summarizes potential safety hazards of combined herb-western drug application. On this basis, critical research bottlenecks are clarified, and future research priorities including high-quality multicenter clinical trials, pharmacokinetic-pharmacodynamic investigation, multi-omics analysis, artificial-intelligence-assisted objective syndrome evaluation, and standardized herbal quality control are proposed. It provides theoretical support for further standardized translational research and full-cycle clinical practice of integrated Chinese-Western medicine for AMI.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-11-17
DOI
https://doi.org/10.3389/fcvm.2026.1990359
Primary Topic
Traditional Chinese Medicine Analysis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Research progress on traditional Chinese medicine intervention in acute myocardial infarction based on syndrome differentiation and treatment

Leiling Shi, Lulu Wang, Long Liu, Ying Liu et al.
1 links
Frontiers in Cardiovascular Medicine
Traditional Chinese Medicine Analysis
article

Research progress on traditional Chinese medicine intervention in acute myocardial infarction based on syndrome differentiation and treatment

Leiling Shi, Lulu Wang, Long Liu, Ying Liu, Jing Zhang, Ruotong Liu
article en

Abstract

Background Acute myocardial infarction (AMI) corresponds to chest impediment and true heart pain in traditional Chinese medicine (TCM), a critical cardiovascular emergency with the core pathogenesis of deficiency in origin and excess in manifestation and six major clinical syndrome patterns. Guideline-directed medical therapy including reperfusion and pharmacotherapy serve as the primary emergency strategy for rescuing ischemic myocardium; nevertheless, drug-related adverse reactions and persistent post-infarction symptomatic complaints remain prevalent. TCM formulae exert multimodal myocardial-protective bioactivities supported mainly by preclinical evidence and can relieve residual discomforts when used as add-on complementary intervention. This highlights the clinical value of pattern identification-based therapeutic management-guided integrated Chinese-Western intervention for AMI. Stand-alone herbal-based TCM intervention cannot replace urgent guideline-directed reperfusion and pharmacological interventions. Aim of the review This narrative review aims to narratively synthesize existing evidence for guideline-directed western-only therapy, TCM adjuvant intervention, and integrated Chinese-Western medicine for AMI, elaborate potential cardioprotective mechanisms of representative TCM prescriptions derived from preclinical experimental observations, analyze superimposed safety risks caused by herbal-western drug concomitant use, and identify prominent evidence gaps, so as to provide theoretical references for standardized integrated Chinese-Western clinical management of AMI. Materials and methods Literature was narratively collected from CNKI and PubMed from database inception up to June 30, 2026. Studies covering preclinical and clinical evidence of guideline-directed western medicine, stand-alone herbal-based TCM intervention, and combined Chinese-Western interventions for AMI were included. Literature screening, data extraction, and narrative synthesis were performed for therapeutic efficacy, cardioprotective mechanisms, and herb-drug interaction risks; major limitations of current research were further summarized. This is not a systematic review. Results preclinical experimental observations suggest multi-target cardioprotective properties of TCM herbs and compound formulae and cannot be directly extrapolated to human clinical outcomes. Available clinical evidence indicates that syndrome-differentiation-guided TCM as an add-on to standard guideline-directed western therapy can alleviate residual discomforts during AMI convalescence, whereas stand-alone herbal-based TCM intervention cannot replace urgent western reperfusion and pharmacological interventions. The high-quality CTS-AMI trial supports adjuvant benefits for Tongxinluo only and cannot be generalized to all TCM herbal preparations. Current research drawbacks include non-unified syndrome-differentiation criteria, insufficient large-sample long-term cohorts focusing on robust clinical outcome metrics, inadequate safety data concerning herbal-western drug concomitant use, publication bias, and heterogeneity across preclinical and clinical studies. Conclusion This review compares the merits and limitations of three interventional modalities for AMI, interprets the theoretical basis and practical value of pattern identification-based therapeutic management-based TCM adjuvant treatment, and summarizes potential safety hazards of combined herb-western drug application. On this basis, critical research bottlenecks are clarified, and future research priorities including high-quality multicenter clinical trials, pharmacokinetic-pharmacodynamic investigation, multi-omics analysis, artificial-intelligence-assisted objective syndrome evaluation, and standardized herbal quality control are proposed. It provides theoretical support for further standardized translational research and full-cycle clinical practice of integrated Chinese-Western medicine for AMI.

Frontiers in Cardiovascular MedicineVol. 13
Xinjiang Institute of Materia Medica (CN), Changchun University of Chinese Medicine (CN), Jilin Agricultural University (CN), Changchun Sci-Tech University (CN)
People's Government of Jilin Province
Good health and well-being
Traditional Chinese Medicine Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon